Harvard Bioscience: Forgotten Stock Poised To Deliver Near-Term Results
- Cash cow business with tremendous operating leverage that is largely ignored post-HART spin-off.
- New management with shareholder-friendly incentives in place focusing on a business that was ignored during the past few years.
- Achievement of cost savings and execution of accretive acquisitions.
- Growth from both pent-up demand and emerging markets.
- Equity research coverage and potential takeover.